Details of the Drug Combination

General Information of Drug Combination (ID: DCMCEK3)

Drug Combination Name
Rifabutin GSK1265744
Indication
Disease Entry Status REF
Infection, Human Immunodeficiency Virus Phase 1 [1]
Component Drugs Rifabutin   DM1YBHK GSK1265744   DMT8J0I
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rifabutin
Disease Entry ICD 11 Status REF
Mycobacterium infection 1B10-1B21 Approved [2]
Tuberculosis 1B10-1B14 Approved [2]
Rifabutin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA-directed RNA polymerase (RNAP) TTHKJLN NOUNIPROTAC Modulator [4]
------------------------------------------------------------------------------------
Rifabutin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [5]
------------------------------------------------------------------------------------
Indication(s) of GSK1265744
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Phase 3 [3]
GSK1265744 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human immunodeficiency virus Integrase (HIV IN) TT5FH9Y POL_HV1B1 Inhibitor [6]
------------------------------------------------------------------------------------
GSK1265744 Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [7]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03149848) Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
2 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
3 ClinicalTrials.gov (NCT02951052) Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults. U.S. National Institutes of Health.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998 Apr;63(4):414-21.
6 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7 Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46(2):147-62.